checkAd

     554  0 Kommentare IntelliCell BioSciences Appoints Mr. Michael Herschman as Chairman of the Board of Directors - Seite 2

    About IntelliCell BioSciences
    IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

    Forward-Looking Statements
    Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    Contact:
    Investors:
    Chris Camarra
    Alliance Advisors, LLC
    Email Contact

    Seite 2 von 2




    Verfasst von Marketwired
    IntelliCell BioSciences Appoints Mr. Michael Herschman as Chairman of the Board of Directors - Seite 2 NEW YORK, NY--(Marketwired - Oct 30, 2013) - IntelliCell BioSciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that …